Use of biologics increases the risk for treatment escalation to systemic therapies among patients with inflammatory acne.

Biologics as a first-line systemic therapy are associated with better clinical outcomes and lower risks for chronic comorbidities in patients with moderate-to-severe psoriasis.

Please provide your email address to receive an email when new articles are posted on . Five factors were identified as reasons why patients avoid treatment with adalimumab and other biologics.

Biologic treatments for eczema are medications usually prescribed for people with moderate to severe disease. These medications are administered by injection and are typically only prescribed when ...

Smoking, higher body mass index (BMI), and previous exposure to biologics were linked to poorer responses to biologics among patients with psoriasis, in a meta-analysis. Older age (odds ratio [OR], ...

Posters presented at the American Academy of Dermatology Annual Meeting identified significant undertreatment of psoriasis and significant gaps in biologic medication treatment. This content was ...

Two posters demonstrated that povorcitinib showed durable 54-week efficacy and a favorable safety profile in moderate to severe HS, including patients previously on anti-TNF therapy. This content was ...

Robust real-world data on the effectiveness of biologic therapies in children with severe asthma remain limited, particularly across different ages and early-life risk profiles. This evidence gap ...

Please provide your email address to receive an email when new articles are posted on . Practices receive biologics directly and then bill the payer for their use. Advantages include improved ...

A new study has found that using biologic therapy to reduce lung inflammation enabled 92% of people with severe asthma to reduce their dose of daily inhaled steroid without exacerbating their symptoms ...